{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:21:06Z","timestamp":1788776466428,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1124\/jpet.114.218081","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T04:02:39Z","timestamp":1410321759000},"page":"403-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients"],"prefix":"10.1016","volume":"351","author":[{"given":"Rucha S.","family":"Sane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard G.","family":"Steinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitha","family":"Podila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry O.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Nehmiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf O.","family":"B\u00f6cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.218081_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/03602530802341133","article-title":"Drug-induced hyperbilirubinemia and the clinical influencing factors","volume":"40","author":"Ah","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1124\/jpet.114.218081_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","article-title":"Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1","volume":"40","author":"Annaert","year":"2010","journal-title":"Xenobiotica"},{"issue":"Suppl 1","key":"10.1124\/jpet.114.218081_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/liv.12424","article-title":"Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir","volume":"34","author":"Asselah","year":"2014","journal-title":"Liver Int"},{"key":"10.1124\/jpet.114.218081_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cbi.2004.08.008","article-title":"Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia","volume":"150","author":"Campbell","year":"2004","journal-title":"Chem Biol Interact"},{"key":"10.1124\/jpet.114.218081_bib5","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1021\/mp4001348","article-title":"Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia","volume":"10","author":"Chang","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.114.218081_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3109\/00498254.2013.820006","article-title":"In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia","volume":"44","author":"Chiou","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.114.218081_bib7","series-title":"The Liver: Biology and Pathobiology","first-page":"291","article-title":"Disorders of bilirubin metabolism","author":"Chowdhury","year":"2001"},{"key":"10.1124\/jpet.114.218081_bib8","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1128\/AAC.02497-13","article-title":"SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon \u03b1-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients","volume":"58","author":"Dieterich","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.114.218081_bib10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1053\/jhep.2002.36368","article-title":"Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome","volume":"36","author":"Hashimoto","year":"2002","journal-title":"Hepatology"},{"key":"10.1124\/jpet.114.218081_bib11","unstructured":"Jacobson IM, Asselah T, Ferenci P, Foster GR, Jensen DM, Negro F, Mantry P, Wright D, Forns X, Garcia-Samaniego J et al.; STARTverso3 Study Group (2013) STARTVerso3: a randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon alpha-2a and ribavirin in treatment-experienced patients with chronic HCV genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2013 November 1\u20135; Washington, DC."},{"key":"10.1124\/jpet.114.218081_bib12","unstructured":"Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Moreno C, Ouzan D, Wright M et al.; STARTVerso1 and STARTVerso2 Study Groups (2013) A pooled analysis of two randomized, double-blind, placebo-controlled phase III trials (STARTVerso1 and 2) of faldaprevir plus pegylated interferon a-2a and ribavirin in treatment-naive patients with chronic hepatitis genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2013 November 1\u20135; Washington, DC."},{"key":"10.1124\/jpet.114.218081_bib13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/clinchem\/48.7.1096","article-title":"Direct spectrophotometric method for measurement of bilirubin in newborns: comparison with HPLC and an automated diazo method","volume":"48","author":"Kazmierczak","year":"2002","journal-title":"Clin Chem"},{"key":"10.1124\/jpet.114.218081_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug-drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/jpet.114.218081_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1542-3565(05)00083-2","article-title":"Hyperbilirubinemia in the setting of antiviral therapy","volume":"3","author":"Korenblat","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.114.218081_bib16","doi-asserted-by":"crossref","unstructured":"Lawitz E, Poordad F, Kowdley KV, Jensen D, Cohen DE, Siggelkow S, Wikstrom K, Larsen L, Menon RM, Podsadecki T et al. (2012) A 12-week interferon-free regimen of ABT-450\/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-na\u00efve HCV IL28B-CC genotype-1-infected subjects. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18\u201322; Barcelona, Spain.","DOI":"10.1016\/S0168-8278(12)60027-0"},{"key":"10.1124\/jpet.114.218081_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/pmj.79.932.307","article-title":"Evaluation of abnormal liver function tests","volume":"79","author":"Limdi","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1124\/jpet.114.218081_bib18","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","article-title":"Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.114.218081_bib19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3851\/IMP1894","article-title":"Rapid viral response of once-daily TMC435 plus pegylated interferon\/ribavirin in hepatitis C genotype-1 patients: a randomized trial","volume":"16","author":"Manns","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1124\/jpet.114.218081_bib20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.218081_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03710708","article-title":"Hepatitis C infection and chronic renal diseases","volume":"4","author":"Perico","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.114.218081_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.218081_bib23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1086\/466531","article-title":"Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia","volume":"192","author":"Rotger","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1124\/jpet.114.218081_bib24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/14622416.9.6.703","article-title":"Pharmacogenetics of Gilbert\u2019s syndrome","volume":"9","author":"Strassburg","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1124\/jpet.114.218081_bib25","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/hep.26276","article-title":"Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-na\u00efve patients with chronic genotype 1 HCV: SILEN-C1 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1124\/jpet.114.218081_bib26","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/hep.26386","article-title":"Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1124\/jpet.114.218081_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.114.218081_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/03602530903491881","article-title":"Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity","volume":"42","author":"Swift","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/jpet.114.218081_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.114.218081_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"key":"10.1124\/jpet.114.218081_bib31","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1128\/AAC.00787-10","article-title":"Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease","volume":"54","author":"White","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.114.218081_bib32","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.218081_bib33","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524188519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.218081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:34:47Z","timestamp":1743201287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524188519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0022356524188519"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.218081","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.218081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}